retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Mounjaro: and Diabetes Triple G Agonists – Retatrutide.

The most common side effects patients report are nausea (55%), diarrhea (12%), and stomach pain (9%)

March 3, 2025: Go-Forward Plan in Ozempic Lawsuits Discussed During Status Hearing In a recent status conference for the Ozempic group lawsuit, Judge Karen Spencer Marston discussed a number of important milestones for GLP-1 lawsuits in 2025

FTC Lawsuit Against PBMs Moves Forward : A federal judge rejected an attempt to block the FTCs lawsuit against major PBMs, including Caremark, Express Scripts, and Optum Rx

Patients at JosephCareRX often report that combining Ozempic with lifestyle modificationssuch as dietary adjustments and regular physical activityenhances its effectiveness, making it a practical option for both diabetes management and weight loss

NASH remains a complex, multifaceted issue with no standard treatment that is currently available 3